Flumethasone pivalate is incorporated into low-dose veterinary oral tablets through a stepwise trituration sequence because direct addition of the micronized pivalate ester at 0.078–0.156 wt% of the final blend introduces unacceptable content uniformity drift in rotary tablet presses operating at production speed. The downstream process begins with a 1:10 to 1:20 pre-blend of flumethasone pivalate and lactose monohydrate in a bin blender at 12–15 rpm for 20–30 minutes. The pre-blend is passed through a 500 µm stainless-steel sieve to break soft agglomerates of the hydrophobic pivalate ester. Subsequent dilution with microcrystalline cellulose, pregelatinized starch, and sodium starch glycolate yields a final blend in which the 0.0625 mg dose in an 80 mg tablet core corresponds to 0.078 wt% API and the 0.125 mg dose corresponds to 0.156 wt%. Direct compression is used only when the final blend exhibits a bulk density of 0.45–0.65 g/mL, a Carr index below 20, and an angle of repose below 35°. If those flow parameters are not achieved, the batch is converted to wet granulation with an aqueous povidone K30 binder solution at 2.0–4.0 wt% of dry granulation mass. Tableting is performed on a rotary press at 8.0–12.0 kN mean compression force and 40–80 rpm turret speed, with a pre-compression force of 1.5–3.0 kN. Film coating is applied in a perforated pan coater using a 12–15% w/w aqueous hydroxypropyl methylcellulose dispersion at an inlet air temperature of 60–70°C and bed temperature of 38–42°C. Finished product classes include round flat-faced bevel-edge scored tablets and oblong film-coated tablets in aluminum/PVC/PVDC blisters. Compliance is anchored to USP <905> with acceptance value L1 ≤ 15.0, USP <711> dissolution testing using Apparatus 2 at 50 rpm in 900 mL of 0.5% sodium lauryl sulfate solution, ICH Q3D for elemental impurities, VICH GL18 for residual solvents, and 21 CFR 211 current good manufacturing practice for finished pharmaceuticals.

What Limits Content Uniformity in 0.125 mg Capsule Filling?

At a nominal capsule fill of 0.125 mg, the limiting variable is not analytical assay sensitivity but the transfer of the micronized pivalate ester across stainless steel contact surfaces and gelatin or HPMC capsule bodies. Flumethasone pivalate is poorly water-soluble and prone to triboelectric charging during low-shear blending, which lowers content uniformity if the final blend is loaded directly at 0.05–0.25 wt% API. The manufacturing process therefore uses a two-stage trituration: the API is first dispersed 1:10 with lactose monohydrate through a 250 µm mesh screen, then re-dispersed 1:10 with a second lactose portion before final blending with pregelatinized starch and sodium starch glycolate in a tumble blender at 12–15 rpm for 25–35 minutes. Blend uniformity is monitored at 10–12 sampling points with a relative standard deviation target below 2.0% before the blend is discharged into a tamping-pin capsule machine or a dosator-type encapsulation machine. The fill weight for size 3 or size 4 hard gelatin or HPMC capsules is maintained at 80–120 mg per capsule, with in-process weight verification every 15 minutes using a 0.1 mg readability balance. Terminal product classes include hard gelatin and HPMC capsules containing 0.0625 mg, 0.125 mg, or 0.25 mg flumethasone pivalate, packaged in HDPE bottles with desiccant or cold-form aluminum blisters. The compliance anchor is USP <905> for uniformity of dosage units, USP <711> for dissolution using Apparatus 2 at 50 rpm in 900 mL of a surfactant-containing dissolution medium, ICH Q3D for elemental impurities, VICH GL18 for residual solvents, and 21 CFR 211 for component testing, master production records, and batch release.

When Fluid-Bed Spray Granulation Replaces Direct Compression for Oral Granules

Oral granules containing flumethasone pivalate are manufactured at an API loading of 0.05–0.20 wt% to deliver 0.1–0.5 mg active ingredient per gram of finished granule. The route is selected when the granulation must disperse in soft feed, drinking water, or a reconstituted oral suspending vehicle, because direct compression cannot provide the required wetting and de-aggregation behavior. The process begins with a pre-blend of flumethasone pivalate and lactose monohydrate that is screened through a 500 µm mesh and then loaded into a fluid-bed granulator equipped with a top-spray insert. An aqueous binder solution of povidone K30 at 2.0–3.0 wt% is sprayed at an inlet air temperature of 55–65°C, product temperature of 30–35°C, atomization air pressure of 1.5–2.0 bar, and spray rate of 10–20 g/min per kg of dry substrate. Drying continues until loss on drying is ≤ 2.0%, followed by sieving through 0.8–1.4 mm screens. Terminal product types include single-dose sachets of 1.0 g or 5.0 g, multi-dose HDPE bottles with a dosing scoop, and bulk granules in polyethylene-lined fiber drums for veterinary repackaging. The finished granules are tested under USP <905> for uniformity of dosage units after reconstitution, USP <711> for dissolution of the dispersed granules, VICH GL18 for residual solvents, ICH Q3D for elemental impurities, and 21 CFR 211 for process validation and batch-to-batch consistency.

An aqueous injectable suspension is formulated at a nominal flumethasone pivalate concentration of 0.5 mg/mL, which equals 0.05% w/v of the micronized active ingredient in the final vehicle. The production route begins with air-jet micronization of the pivalate ester to a D(0.9) below 10 µm, followed by wet bead milling in a stainless-steel bead mill with 0.5 mm yttrium-stabilized zirconia grinding media at 2500–3000 rpm for 30–45 minutes. The aqueous vehicle is prepared separately with sodium citrate dihydrate as a buffering agent, polysorbate 80 as a wetting agent at 0.1–0.2% w/v, and sodium carboxymethylcellulose as a suspending agent to achieve a finished viscosity between 150 mPa·s and 350 mPa·s at 25°C. The sterilized vehicle and the micronized API dispersion are combined under unidirectional airflow in an ISO Class 5 environment according to ISO 14644-1:2015, then filled into borosilicate Type I glass vials. Terminal product classes include multi-dose vials of 10 mL, 50 mL, and 100 mL with bromobutyl rubber stoppers and aluminum flip-off seals. Compliance is anchored to USP <1> for injectable volume and container requirements, USP <71> for sterility, USP <85> for bacterial endotoxins, USP <788> for particulate matter, EU GMP Annex 1 for sterile manufacturing, and 21 CFR 211 for finished pharmaceutical current good manufacturing practice.

Terminal Moist-Heat Sterilization Versus Aseptic Filling of 0.5 mg/mL Suspensions

Terminal moist-heat sterilization remains the preferred route for a 0.5 mg/mL flumethasone pivalate aqueous suspension when particle-size distribution, suspension rheology, and primary packaging can tolerate thermal load. A water-spray autoclave cycle at 121.1°C for 15 minutes is used to achieve a minimum F₀ of 15.0 in the cold spot of the load. The same concentration, 0.05% w/v, is filled into depyrogenated Type I glass vials that are sealed with chlorobutyl stoppers before loading into the sterilizer. Process validation includes thermocouple mapping of the slowest-heating container and biological indicators with Geobacillus stearothermophilus spores. Published data for this specific thermal cycle applied to flumethasone pivalate is limited, so terminal-sterilization validation relies on pre- and post-sterilization particle-size comparison and a defined resuspendability endpoint. If the post-sterilization D(0.9) measurement shifts by more than 2–3 µm relative to the pre-filtration suspension, the formulation is diverted to aseptic processing until the suspending agent and surfactant concentrations are re-optimized. Terminal product types are terminally sterilized multi-dose vials and aseptically processed single-dose vials for intramuscular or subcutaneous veterinary use. The compliance framework is identical to the injectable route: USP <71> for sterility, USP <85> for endotoxin, USP <788> for particulate matter, USP <1> for injections, EU GMP Annex 1 for sterile process design, and 21 CFR 211 for batch records and release testing.

Multi-Dose Vial Resuspendability Specifications and Fill-Volume Control

For multi-dose vials of flumethasone pivalate aqueous suspension at 0.5 mg/mL, the fill-volume overage and the resuspendability specification govern batch release as much as active-ingredient content. The fill volume is set to 0.15–0.30 mL above the label claim to meet the withdrawable-volume requirement under USP <1> without excessive overfill. Before sampling, the vial is subjected to a specified resuspendability test consisting of three cycles of manual inversion for 10–15 seconds, followed by visual confirmation that no compacted cake remains on the vial base. The suspension at 0.05% w/v is then drawn through a 21 G needle to verify that the delivered dose is not impaired by needle clogging. In-process filling is performed on a peristaltic or rotary piston filling line with in-line checkweighing every 10–15 minutes to maintain a coefficient of variation below 1.5%. Terminal product classes are multi-dose vials of 10 mL or 50 mL with bromobutyl elastomeric closures and aluminum overseals, labeled for intramuscular or subcutaneous veterinary administration. Compliance is established through USP <1> volume deliverability, USP <788> particulate matter limits for injections, USP <71> sterility, and 21 CFR 211 packaging and labeling controls.